Printer Friendly

NEORX ACQUIRES PRE-TARGETING TECHNOLOGY FROM STANFORD UNIVERSITY

    NEORX ACQUIRES PRE-TARGETING TECHNOLOGY FROM STANFORD UNIVERSITY
    SEATTLE, Feb. 13 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) announced today that it has acquired an exclusive worldwide license from Stanford University for its patented pre-targeting technology.  This technology is designed to increase safety and efficacy of cancer treatment.
    A major hurdle in the development of effective radioimmunotherapy for cancer has been the inability to deliver a therapeutic dose to the tumor without causing toxicity to normal tissues, such as bone marrow.
    Pre-targeting involves injecting the antibody and the radioisotope separately, which then join in the patient's body at the site of the tumor.  Because the radioisotope is attached to a small molecule, any radiation that does not bind to the tumor is rapidly eliminated from the body.  The result is that more radiation reaches the tumor with less toxicity to normal organs.  The advantages of the pre-targeting approach have been shown in animal studies and in imaging studies in humans.
    By contrast, conventional technology developed in the 1940s uses a radioisotope that is attached to an antibody.  This radioactive conjugate is then injected as one large molecule that remains in a patient's bloodstream longer than the radioisotope injected alone, exposing normal tissues to higher doses of radiation.  One result has been toxicity to the bone marrow.
    "The pre-targeting technology may provide the basis for a safe and effective cancer therapy, and constitutes a fundamental proprietary position in the targeted field," said John R. Reno, Ph.D., NeoRx's director, research and product development.  "In addition, because NeoRx has already solved the problem of stably linking various radionuclides to antibodies, as demonstrated in human clinical trials with high doses of radioactivity, we have the companion technologies to make pre- targeting effective.  This approach promises to be exceptionally valuable in a variety of applications that we are now beginning to explore.  We expect it to be an important new weapon in the treatment of cancer."
    NeoRx Corporation, incorporated in May 1984, is developing monoclonal antibody-based pharmaceutical products for in vivo detection and treatment of certain types of cancer.  The company has three cancer therapy trials in progress and has filed for marketing approval with the FDA for two OncoTrac(R) imaging products to detect metastic melanoma and small cell lung cancer.  In addition, the company has completed a phase III trial for detecting non-small cell lung cancer.
    -0-             2/13/92
    /CONTACT:  Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519, or Anthony J. Russo, or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
    (NERX) CO:  NeoRx Corporation; Stanford University ST:  Washington IN:  MTC SU:  LIC PS -- NY007 -- 9552 02/13/92 08:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 13, 1992
Words:445
Previous Article:FORD YEAR-END FINANCIAL RESULTS
Next Article:TARGETED GENETICS, FRED HUTCHINSON CANCER RESEARCH CENTER RECEIVE APPROVAL TO BEGIN HUMAN GENE THERAPY TRIAL
Topics:


Related Articles
NEORX REPORTS BENEFITS OF LUNG CANCER IMAGING PRODUCTS AND STATUS OF CANCER THERAPY DEVELOPMENT PROGRAM
NEORX DECLARES DIVIDEND
NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT
NEORX APPOINTS ROBERT SCHROFF AS VICE PRESIDENT & GENERAL MANGER, CARDIOVASCULAR PRODUCTS
NEORX REPORTS FIRST QUARTER 1993 RESULTS
NEORX PROMOTES ROBERT LITTAUER TO SENIOR VICE PRESIDENT
NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT
NEORX REPORTS SECOND QUARTER 1993 RESULTS
NEORX REPORTS 1994 FIRST QUARTER RESULTS
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF VERLUMA(TM), SMALL CELL LUNG CANCER IMAGING AGENT DEVELOPED BY NEORX

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters